Stock Market Reviews

ATRA (Atara Biotherapeutics, Inc.) News

Get the latest news, insights, and market updates on ATRA (Atara Biotherapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Adma Biologics (ADMA) Q3 Earnings Match Estimates
  Adma Biologics (ADMA) delivered earnings and revenue surprises of 0.00% and +3.17%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025 - $ATRA
• Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
  Pierre Fabre Pharmaceuticals Inc. (PFP) announces the transfer of the Biologics License Application (BLA) for tabelecleucel from Atara Biotherapeutics Inc. (Nasdaq: ATRA) with PFP now accountable for all aspects of the submission. Atara will continue to observe the regulatory process and provide support to PFP as needed. The tabelecleucel BLA has an FDA PDUFA target action date of January 10, 2026. If approved, the tabelecleucel will be indicated as monotherapy for treatment of adult and pediatr
  Nov 3, 2025 - $ATRA
• While institutions own 28% of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), individual investors are its largest shareholders with 35% ownership
  Key Insights The considerable ownership by individual investors in Atara Biotherapeutics indicates that they...
  Oct 3, 2025 - $ATRA
• Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock?
  Atara Biotherapeutics (ATRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
  Sep 25, 2025 - $ATRA
• Atara Biotherapeutics Announces Changes to Its Board of Directors
  THOUSAND OAKS, Calif, September 03, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Greg Ciongoli will assume the role of Chair of the Board of Directors.
  Sep 3, 2025 - $ATRA
• In cell therapy, cost is a hot issue. The industry might need a cold solution.
  The logistical linchpin of cryopreservation could make a challenging space more accessible.
  Aug 19, 2025 - $ATRA
• Atara Biotherapeutics Second Quarter 2025 Earnings: Beats Expectations
  Atara Biotherapeutics ( NASDAQ:ATRA ) Second Quarter 2025 Results Key Financial Results Revenue: US$17.6m (down 39...
  Aug 14, 2025 - $ATRA
• Atara Biotherapeutics: Q2 Earnings Snapshot
  ATRA) on Monday reported second-quarter net income of $2.4 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Thousand Oaks, California-based company said it had net income of 19 cents. The drug developer posted revenue of $17.6 million in the period.
  Aug 11, 2025 - $ATRA
• Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
  THOUSAND OAKS, Calif., August 11, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2025 and business updates.
  Aug 11, 2025 - $ATRA
• Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Is About To Turn The Corner
  We feel now is a pretty good time to analyse Atara Biotherapeutics, Inc.'s ( NASDAQ:ATRA ) business as it appears the...
  Aug 5, 2025 - $ATRA